137 related articles for article (PubMed ID: 33031248)
1. An Incidental Uptake of 18F-Choline at PET/CT in Gastric Neuroendocrine Tumor.
Evangelista L; Cassarino G; Capobianco D; Povolato M; Battista S; Rensi M
Clin Nucl Med; 2021 Apr; 46(4):e238-e239. PubMed ID: 33031248
[TBL] [Abstract][Full Text] [Related]
2. Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors: A Feasibility Study.
Thuillier P; Maajem M; Schick U; Blanc-Beguin F; Hennebicq S; Metges JP; Salaun PY; Kerlan V; Bourhis D; Abgral R
Clin Nucl Med; 2021 Feb; 46(2):111-118. PubMed ID: 33234927
[TBL] [Abstract][Full Text] [Related]
3. Is 18F-Fluorodeoxyglucose the Tracer of Choice for Functional Imaging of Neuroendocrine Tumors Grade 3? A Case Report.
Lorusso M; Inzani F; Castaldi P; Menghi R; Schinzari G; Rindi G; Rufini V
Pancreas; 2018 Apr; 47(4):e20-e22. PubMed ID: 29521949
[No Abstract] [Full Text] [Related]
4. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
5. Lutetium lu 177 dotatate (Lutathera) for gastroenteropancreatic neuroendocrine tumors.
Med Lett Drugs Ther; 2018 Sep; 60(1555):e152-e153. PubMed ID: 30383735
[No Abstract] [Full Text] [Related]
6. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
[TBL] [Abstract][Full Text] [Related]
7. Could the skewness and kurtosis texture parameters of lesions obtained from pretreatment Ga-68 DOTA-TATE PET/CT images predict receptor radionuclide therapy response in patients with gastroenteropancreatic neuroendocrine tumors?
Önner H; Abdülrezzak Ü; Tutuş A
Nucl Med Commun; 2020 Oct; 41(10):1034-1039. PubMed ID: 32516240
[TBL] [Abstract][Full Text] [Related]
8. Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors.
Ansquer C; Touchefeu Y; Faivre-Chauvet A; Leux C; Le Bras M; Régenet N; Fleury V; Maucherat B; Senellart H; Guyetant S; Carlier T; Scotet-Cérato E; Rauscher A; Frampas E; Kraeber-Bodéré F
Clin Nucl Med; 2021 Mar; 46(3):181-186. PubMed ID: 33315677
[TBL] [Abstract][Full Text] [Related]
9. False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (
Berends AMA; Kerstens MN; Bolt JW; Links TP; Korpershoek E; de Krijger RR; Walenkamp AME; Noordzij W; van Etten B; Kats-Ugurlu G; Brouwers AH; van der Horst-Schrivers ANA
Eur J Endocrinol; 2018 Aug; 179(2):125-133. PubMed ID: 29875288
[TBL] [Abstract][Full Text] [Related]
10. Safety, Biodistribution, and Radiation Dosimetry of
Nicolas GP; Beykan S; Bouterfa H; Kaufmann J; Bauman A; Lassmann M; Reubi JC; Rivier JEF; Maecke HR; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):909-914. PubMed ID: 29025985
[TBL] [Abstract][Full Text] [Related]
11. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?
Ezziddin S; Lohmar J; Yong-Hing CJ; Sabet A; Ahmadzadehfar H; Kukuk G; Biersack HJ; Guhlke S; Reichmann K
Clin Nucl Med; 2012 Jun; 37(6):e141-7. PubMed ID: 22614212
[TBL] [Abstract][Full Text] [Related]
12. Recurrence of Extramedullary Plasmacytomas Involving Lymph Nodes and Pancreas Revealed by 68Ga-DOTATATE and 18F-FDG PET/CT.
Pan Q; Luo Y; Li J; Zhang S; Li F
Clin Nucl Med; 2018 Dec; 43(12):936-938. PubMed ID: 30179917
[TBL] [Abstract][Full Text] [Related]
13. Can PET/CT guide the personalized treatment of patients with gastroenteropancreatic neuroendocrine neoplasms?
Schillaci O
J Nucl Med; 2014 Nov; 55(11):1757-8. PubMed ID: 25342386
[No Abstract] [Full Text] [Related]
14. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
[TBL] [Abstract][Full Text] [Related]
15. Diffuse Bone Metastases in Pancreatic Neuroendocrine Tumor Shown on Octreoscan.
Adkins J; Lu Y
Clin Nucl Med; 2019 Mar; 44(3):257-258. PubMed ID: 30624276
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Contrast-Enhanced CT + CT Enterography and 68Ga-DOTANOC PET/CT in Gastroenteropancreatic Neuroendocrine Tumors.
Sharma A; Das CJ; Makharia GK; Arora G; Kumar R
Clin Nucl Med; 2020 Nov; 45(11):848-853. PubMed ID: 32657875
[TBL] [Abstract][Full Text] [Related]
17. The Correlation Between [
Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary neuroendocrine tumor incidentally detected by (18)F-CH PET/CT.
Treglia G; Lococo F; Petrone G; Inzani F; Perotti G; Porziella V; Granone P; Rindi G; Giordano A; Rufini V
Clin Nucl Med; 2013 Apr; 38(4):e196-9. PubMed ID: 23446117
[TBL] [Abstract][Full Text] [Related]
19. 68Ga-Prostate-Specific Membrane Antigen Uptake in a Pancreatic Neuroendocrine Tumor.
Luong TV; Iversen P; Bouchelouche K; Arveschoug AK
Clin Nucl Med; 2020 May; 45(5):379-382. PubMed ID: 32149792
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of Radio-Guided Surgery with ⁶⁸Gallium-DOTATATE in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors.
Sadowski SM; Millo C; Neychev V; Aufforth R; Keutgen X; Glanville J; Alimchandani M; Nilubol N; Herscovitch P; Quezado M; Kebebew E
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S676-82. PubMed ID: 26350374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
